Oridion Microstream(R) Technology to be Incorporated Into Market Leader's
Patient-Controlled Analgesia (PCA) Device
JERUSALEM and NEEDHAM, MA, Jan. 15 /CNW/ - Oridion Systems Ltd. (SIX
Swiss Exchange: ORIDN) today announced an agreement with a global healthcare
company that is a market leader in medication infusion systems. Under this
agreement, Oridion's Capnostream(TM) carbon dioxide (CO2) monitor using
Microstream(R) capnography technology will be incorporated into a PCA infusion
device at a future date, allowing hospital patients to control the flow of
their pain medication within specified limits.
By enabling connectivity between the Capnostream and PCA device,
clinicians will be able to monitor their patients' end tidal (CO2) levels.
Clinicians using Microstream are more likely to detect respiratory depression
than clinicians monitoring with pulse oximetry alone.(1) This is particularly
important when administering potent pain medication.
The ability to monitor CO2 levels is vital. It can alert clinicians to
episodes of hypoventilation as well as help them assess ventilation and
treatment of asthma and chronic obstructive pulmonary disease (COPD) in
patients. This is the reason why organizations, such as the Anesthesia Patient
Safety Foundation (APSF)(2) and the American Society of Anesthesiologists
(ASA)(3) recommend ventilatory monitoring when administering opiates and
during procedural sedation. Patient-controlled analgesia systems are used in
"More and more hospital systems are becoming proactive about instituting
policies to assure patient safety when potent drugs are used," said Gerry
Feldman, president of Oridion. "It is good to see that the hospital community
recognizes the importance of monitoring ventilation effectively, a necessity
to safely eliminate unnecessary patient pain, a Joint Commission mandate. Our
newest partner has selected Oridion, the world-wide leader in capnography
monitoring, as an additional important step in their commitment to help
hospitals reduce medication errors, improve patient safety and adhere to best
Further details regarding this agreement were not disclosed.
Oridion Systems Ltd. (http://www.oridion.com) is a global medical device
company specializing in patient safety monitoring. The Company operates
through wholly owned subsidiaries in the United States, Europe, and Israel.
Oridion develops proprietary medical devices and patient interfaces,
based on its patented Microstream(R) technologies, for the enhancement of
patient safety through the monitoring of the carbon dioxide (CO2) in a
patient's breath. These products provide effective, proven airway management
and are used in various clinical environments, including procedural sedation,
pain management, operating rooms, critical care units, post-anesthesia care
units, emergency medical services, transport, alternate care and other
settings where patients' ventilation may be compromised and at risk.
(1) Jonathan B. Waugh, PhD, RRT, RPFT; Yulia Khodneva, MD; Chad A. Epps,
MD, Monitoring to Improve Ventilation Safety during Sedation and Analgesia.
Society for Technology in Anesthesia 2008.
(2) Anesthesia Patient Safety Foundation (APSF) Newsletter, Winter
2006-2007, Vol. 21, 4.
(3) American Society of Anesthesiologists Task Force on Sedation and
Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and
analgesia by non-anesthesiologists. Anesthesiology. 2002; 96(4):1004-17.
For further information:
For further information: Alan Adler, Chairman and Chief Executive
Officer; Walter Tabachnik, Chief Financial Officer; Elena Gerberg, Investor
Relations; e-mail: email@example.com, website: http://www.oridion.com,
phone: +972-2-589-9159, address: Oridion Systems Ltd., P.O. Box 45025, 91450